Prestige Brands Navigates Converting M&A Into Organic Growth
This article was originally published in The Tan Sheet
Executive Summary
Prestige Brands reports 2.6% growth in latest quarter to $165.1m in US sales of OTC drugs including BC and Goody's analgesic brands and Ludens and Chloraseptic throat lozenge brands, but international sales, a focus area for growth, dropped 11.2% to $13.8m due to currency exchange rates.